264 related articles for article (PubMed ID: 22761788)
1. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
2. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
Dons EM; Raimondi G; Zhang H; Zahorchak AF; Bhama JK; Lu L; Ezzelarab M; Ijzermans JN; Cooper DK; Thomson AW
Am J Transplant; 2013 Aug; 13(8):2169-78. PubMed ID: 23635093
[TBL] [Abstract][Full Text] [Related]
4. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
6. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.
Ambrose LR; Morel AS; Warrens AN
Blood; 2009 Oct; 114(14):3052-5. PubMed ID: 19638623
[TBL] [Abstract][Full Text] [Related]
7. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
Pulaski HL; Spahlinger G; Silva IA; McLean K; Kueck AS; Reynolds RK; Coukos G; Conejo-Garcia JR; Buckanovich RJ
J Transl Med; 2009 Jun; 7():49. PubMed ID: 19545375
[TBL] [Abstract][Full Text] [Related]
8. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
[TBL] [Abstract][Full Text] [Related]
9. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
Buggins AG; Mufti GJ; Salisbury J; Codd J; Westwood N; Arno M; Fishlock K; Pagliuca A; Devereux S
Blood; 2002 Sep; 100(5):1715-20. PubMed ID: 12176892
[TBL] [Abstract][Full Text] [Related]
11. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
12. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
Mone AP; Cheney C; Banks AL; Tridandapani S; Mehter N; Guster S; Lin T; Eisenbeis CF; Young DC; Byrd JC
Leukemia; 2006 Feb; 20(2):272-9. PubMed ID: 16341049
[TBL] [Abstract][Full Text] [Related]
14. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Turner MJ; Lamorte MJ; Chretien N; Havari E; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2013 Aug; 261(1-2):29-36. PubMed ID: 23759318
[TBL] [Abstract][Full Text] [Related]
15. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
16. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD52 in peripheral T-cell lymphoma.
Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
[TBL] [Abstract][Full Text] [Related]
19. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
[TBL] [Abstract][Full Text] [Related]
20. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
